Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Co-development of efflux pump inhibitors with antibiotics on targeting structural and mutational aspects of AcrB subunit.

Molecular diversity - 1 Feb 2026

Chauhan Shweta Singh, Jamal Tanya, Gupta Anshika, Parthasarathi Ramakrishnan

Abstract excerpt

The rise of antimicrobial resistance (AMR) of the routinely used antibiotics is ineffective against drug-resistant pathogenic strains of Escherichia coli, set off with limited treatment choices, costs, and increasing mortality rates. Multidrug efflux pumps have been identified as crucial determinants of AMR, flushing numerous antibiotics from cells in a non-specific way, and have emerged as promising drug targets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Escherichia coli

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Escherichia coli Proteins

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Mutation

Source

Identifiers

PMID: 40287901
DOI: 10.1007/s11030-025-11204-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Co-development of efflux pump inhibitors with antibiotics on targeting structural and mutational aspects of AcrB subunit.PMID 40287901Read ↗

Molecular determinant deciphering of MIC-guided RND efflux substrates in E. coliSemantic proximity Read ↗

Drug Efflux Pump Inhibitors: A Promising Approach to Counter Multidrug Resistance in Gram-Negative Pathogens by Targeting AcrB Protein from AcrAB-TolC Multidrug Efflux Pump from Escherichia coliSemantic proximity Read ↗

Identification of Binding Sites for Efflux Pump Inhibitors of the AcrAB-TolC Component AcrA.Semantic proximity Read ↗

AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.Semantic proximity Read ↗

Allosteric drug transport mechanism of multidrug transporter AcrB.Semantic proximity Read ↗

Natural Alkaloid Berberine Activity against Pseudomonas aeruginosa MexXY-Mediated Aminoglycoside Resistance: In Silico and in Vitro StudiesSemantic proximity Read ↗

Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane Fusion Protein of the AcrAB-TolC Multidrug Efflux PumpSemantic proximity Read ↗

Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative BacteriaSemantic proximity Read ↗

Efflux Pumps of Gram-Negative Bacteria, a New Target for New MoleculesSemantic proximity Read ↗

RND-type drug eﬄux pumps from Gram-negative bacteria: molecular mechanism and inhibitionSemantic proximity Read ↗

Mutation-driven alterations in the AcrB efflux pump modulate antibiotic resistance in Klebsiella pneumoniae.Semantic proximity Read ↗

Exploring the potential role of GyrA inhibiting quinoline analog: an in silico studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.